Abstract
Introduction Wilson disease (WD) is a rare autosomal recessively inherited disorder of copper metabolism with pathological copper accumulation mainly in the liver and brain. Chelators are mainly used as treatment for WD. In Germany D-penicillamine is approved as first-line treatment and Trientine (Trientine dihydrochloride (TETA-2HCl) and Trientine tetrahydrochloride (TETA-4HCL)), is available for patients who are intolerant to D-penicillamine. Data on therapy management of patients, specifically with respect to treatment switch and dosing, is rare. Aim This secondary use of data (SUD) project aims to assess retrospective real-world data regarding the diagnostic and therapeutic management, duration, sequence, and dosing of the different therapeutic options in specialized WD centres in Germany. Method In this project, anonymized data from WD patients who received Trientine therapy at least once during their course of treatment in the period of 1.01.2012 and 31.12.2021 and had one or more documented follow-up visits will be included. During the observation period D-Penicillamine, Zinc and two formulations of Trientine (TETA-2HCl and TETA-4HCl) were available. We aim to include 6 German WD centers and up to 150 patients. A questionnaire will be used to capture centre structure, WD diagnoses and therapeutic standards. Additionally, a second questionnaire will collect data for each suitable patient regarding the disease and therapy history. This includes all previous and the current treatments, switching between therapies, the duration of the treatments as well as the duration of the de-coppering phase and the maintenance phase. Furthermore, the dosage of said therapies during de-coppering and maintenance phase will be provided. Results The obtained data will be analysed using exploratory analysis (descriptive analysis/graphical display) based on the various aspects of the treatment management of WD patients. This includes demographic values as well as the number of treatment sequences, dosages prescribed during the different sequences and comparing the de-coppering and maintenance phase. Furthermore, a possible influence of the demographic factors and symptomatic classifications on therapy management will be investigated. Conclusion This project will contribute to a better understanding of the therapy management of WD patients in German specialized WD centres and might support physicians in future therapy decisions. Article published online: 28 August 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany